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Abstract
Introduction: Despite its controversial history, electroconvulsive therapy is generally an effective
treatment with few serious side effects. One rare but troublesome side effect of electroconvulsive
therapy is mania.
Case presentation: A 33-year-old Turkish woman developed mania on three separate occasions
after receiving electroconvulsive therapy for severe depressive episodes.
Conclusion:  Patients who experience electroconvulsive therapy-related mania should be
evaluated for alternative treatments when presenting with severe depression.
Introduction
Electroconvulsive therapy (ECT) has been in use for
almost half a century. It is a safe and efficient treatment
method for numerous psychiatric disorders if scientific
criteria and principles are observed in both the selection
of patients and the implementation of the treatment [1-
3]. ECT is known to cause certain side effects including
cognitive dysfunction, cardiovascular problems, and in
rare cases, mania [4,5]. In ECT-related mania, one may
choose either to cease or to continue treatment [2,6,7].
Case presentation
A 33-year-old Turkish woman presented with a decrease
in psychomotor activation (PMA) and self-care, dyspho-
ria, insomnia, and persecutory delusions. She was hospi-
talized with the preliminary diagnosis of "major
depression with psychotic features," according to DSM-IV
criteria. The patient was not addicted to alcohol or any
illicit substances. Her score on the 17-item Hamilton
Depression Rating Scale (HAMD-17) was 46, indicating
very severe depression. Full laboratory investigations were
in the normal range. She was commenced on haloperidol,
20 mg/day, and biperiden, 4 mg/day, and was given seven
sessions of ECT, as described in detail below. Increases in
PMA, euphoria and grandiosity were observed after the
seventh ECT treatment. Subsequently ECT was stopped,
and lithium, 900 mg/day, was added to the treatment. Her
score on the Young Mania Rating Scale (YMRS) was 28,
and her score on the HAMD-17 was less than 7. Her
mania and depression severity were, respectively, moder-
ate and normal. The patient was discharged with a pre-
scribed treatment of lithium, 900 mg/day, (serum level:
0.6 mg/dL) and chlorpromazine, 300 mg/day.
Although she complied fully with her medications ini-
tially, she stopped taking them 2 years later during preg-
nancy. Following her pregnancy, at the early phase of the
postpartum period, she was hospitalized again with a
diagnosis of "major depressive episode." Her HAMD-17
score of 42 indicated very severe depression. Initially, the
patient was commenced on diazepam, 15 mg/day, which
was stopped and followed by ECT. She was observed to be
too active after the second ECT, and it was stopped after
the third ECT session. Symptoms at this point included
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excessive speaking, euphoria and restlessness. Her YMRS
score of 24 indicated moderate severity of mania. Since
this was judged to be an ECT-induced mania, she was
commenced initially on haloperidol, 20 mg/day, and
biperiden, 4 mg/day, which was changed to lithium, 900
mg/day. She was discharged with a recommended treat-
ment of lithium, 1200 mg/day (serum level: 0.76 mg/dL),
and chlorpromazine, 300 mg/day.
After 21 months, she was re-hospitalized with the initial
diagnosis of "major depressive episode". She presented
with a depressive melancholic mood, and suffered from
persecutory delusions. Her HAMD-17 score was 42. Labo-
ratory investigations were in the normal range except thy-
roid function test (TFT) levels. There was a decrease in fT4
0.8 ng/dl (normal range: 0.93 to 1.7 ng/dl) level, and a
normal range in fT3 3.48 pg/ml (normal range: 2.0 to 4.4
pg/ml) and TSH 2.03 uIU/ml (normal range: 0.27 to 4.2
uIU/ml) levels. After four weeks, her TFT levels were re-
measured in the normal range. Also in her previous epi-
sodes, TFT levels were found to be normal. Treatment with
haloperidol, 30 mg/day, biperiden, 4 mg/day, and
diazepam, 10 mg/day, was not satisfactory. The patient
had total of five ECTs, but was discharged from the hospi-
tal against medical advice, which was then followed by
some improvement.
Six months later, she was re-hospitalized with a similar
presentation, and was commenced on haloperidol, 30
mg/day, biperiden and 4 mg/day. After five sessions, ECT
was stopped due to the emergence of symptoms of exces-
sive speaking, lack of calmness, elation and restlessness.
Her YMRS score was 24. Laboratory investigations were in
the normal range. She was discharged from the hospital
with a medication consisting of haloperidol, 20 mg/day,
biperiden, 4 mg/day, and carbamazepine, 400 mg/day.
This treatment led to a partial improvement in her major
psychiatric symptoms. The patient attended the outpa-
tient clinic in the month after her discharge from hospital.
She had full remission, which was taken to imply an
improvement in both her clinical symptoms and func-
tional disability.
The patient was given unmodified ECT with no anaesthe-
sia during three hospitalizations, and modified ECT with
anaesthesia and muscle relaxants during the last hospital-
ization. In this case, ECT was administered in three ses-
sions a week for all inpatient treatments. ECT was
recommended, and consent was obtained from the
patient and her husband. This informed consent proce-
dure was applied according to approved legal and ethical
practices for people with mental illness in Turkey. A Thy-
matron® system IV-Integrated ECT Instrument (Somatics,
LLC; Lake Bluff, IL) was used. Standard bifrontotemporal
electrode placements were employed for bilateral ECT. In
the first ECT session, a stimulus dose was selected to pro-
duce an intense seizure. For bilateral electrode placements
a dose in miliCoulombs (mC) equal to 3.5 to 4 times the
patient's age sufficed (an initial dose of 126 mC, with an
ECT dose ranging from 118 mC to 120 mC). A seizure
threshold of 126 mC resulted in a 129-second EEG, a 32-
second motor seizure, and a postictal suppression index
(PSI) of 80%. For other ECTs, the stimulus dosage range
was between 118 mC to 120 mC, which elicited a seizure
duration of 15 to 26 seconds. Ventilation was applied
using a face mask during seizures, and oxygenation of the
patient was monitored.
In summary, the patient was hospitalized on four separate
occasions with the diagnosis of "major depression with
psychotic features," and developed ECT-related mania
during three of these episodes. All depressive episodes
were attributable to a failure to use medication regularly
or to a cessation of medication. Eventual clinical improve-
ment in all episodes was achieved by resumption of psy-
chiatric medication.
Discussion
Electroconvulsive therapy is generally used on severely
depressed patients when other forms of therapy, such as
medications or psychotherapy, have not been effective, or
cannot be tolerated, or, in life-threatening cases, will not
help the patient quickly enough. ECT also helps patients
who suffer with prolonged or severe episodes of mania,
although mood stabilizers and antipsychotics are the
mainstay of mania treatment [2,5,7].
Researchers still do not know how ECT works. There are
several major theories that attempt to explain why it
works. The neurotransmitter theory suggests that ECT
works like anti-depressant medication in changing the
way receptors receive mood related chemicals like serot-
onin [8-10]. The anticonvulsant theory proposes that the
induced seizures teach the brain to resist seizures. This
effort to inhibit seizures dampens abnormally active brain
circuits, stabilizing mood [8-10]. The neuroendocrine the-
ory hypothesizes that the seizure causes the hypothala-
mus to release chemicals that cause changes throughout
the body [9].
ECT affects the brain by increasing metabolism and blood
flow to certain parts of the brain; however, it is not known
how this increased blood flow alleviates depression [10].
Recent studies in animals suggest that ECT has potent
effects in bolstering neuronal survival. In common with
chemical antidepressant treatments, CT enhances the
expression of a neuroprotective protein, brain-derived
neurotrophic factor (BDNF), which antagonises the neu-
rotoxic effects of stress on the brain [8].Publish with BioMed Central    and   every 
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Angst's results show that 64 of the 908 patients (7.0%)
admitted for depression switched to hypomania or mania
in a study between 1920 and1982. The switch rate is
mainly explained by polarity; patients with a previous his-
tory of mania and/or hypomania have switch rates of 21%
(mania to depression) to 29% (depression to mania)
[11,12].
While many switches observed in depressive patients may
be due to disease course, we believe that the timing in this
case is highly suggestive of ECT-related mania. Interest-
ingly, our patient never experienced mania without first
undergoing ECT. Some clinicians argue that in cases such
as ours, limbic stimulation by ECT exceeded the affective
target, resulting in mania [13]. Once the patient became
manic, we had the choice to continue or to cease ECT.
Because the severity of mania was moderate, the decision
was made to use a pharmacologic approach [14-16]. Med-
ications proved adequate in treating a future episode of
major depression with psychosis.
Conclusion
In deciding whether to administer ECT to a patient who
has experienced ECT-related mania, one must weigh the
risks and benefits of such a treatment. The severity of our
patient's depression seemed to indicate ECT on several
admissions, while the side effect of mania was a substan-
tial risk. We suggest that a history of ECT-related mania
should be considered when choosing treatments in
patients with depressive episodes.
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